Advanced glycosylation end products up-regulate connective tissue growth factor (insulin-like growth factor-binding protein-related protein 2) in human fibroblasts: A potential mechanism for expansion of extracellular matrix in diabetes mellitus

Endocrinology

Volumn 142, Issue 5, 2001, Pages 1760-1769

  Twigg, Stephen M ^a   Chen, Michelle M ^b   Joly, Alison H ^b   Chakrapani, Sanjay D ^a   Tsubaki, Junko ^a   Kim, Ho Seong ^a   Oh, Youngman ^a   Rosenfeld, Ron G ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b SCIOS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR;

ANGIOGENESIS; ARTICLE; DIABETES MELLITUS; EXTRACELLULAR MATRIX; FIBROSIS; GLYCOSYLATION; HUMAN; HUMAN CELL; PATHOGENESIS; PRIORITY JOURNAL;

EID: 0035047352     PISSN: 00137227     EISSN: None     Source Type: Journal    
DOI: 10.1210/endo.142.5.8141     Document Type: Article

References (55)

1. Theoretical mechanisms by which hyperglycemia and insulin resistance could cause cardiovascular diseases in diabetes
2. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage
3. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept
4. Advanced glycation end products in children and adolescents with diabetes: Relation to glycemic control and early microvascular complications
5. Formation of immunochemical advanced glycosylation end products precedes and correlates with early manifestations of renal and retinal disease in diabetes
6. Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM
7. Nonenzymatic glycosylation: Role in the pathogenesis of diabetic complications
8. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs
9. Cellular receptors for advanced glycation end products. Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions
10. Negative consequences of glycation
11. Receptor-mediated interactions of advanced glycosylation end products with cellular components within diabetic tissues
12. Advanced glycation end products induce expression of vascular endothelial growth factor by retinal Muller cells
13. Upregulation of mesangial growth factor and extracellular matrix synthesis by advanced glycation end products via a receptor-mediated mechanism
14. Administration of AGEs in vivo induces extracellular matrix gene expression
15. Advanced glycation end products up-regulate gene expression found in diabetic glomerular disease
16. The effect of advanced glycation end-product formation upon cell-matrix interactions
17. Recommendations for nomenclature of the insulin-like growth factor binding protein superfamily
18. Stimulation of fibroblast cell growth, matrix production, and granulation tissue formation by connective tissue growth factor
19. Connective tissue growth factor: A mediator of TGF-β action on fibroblasts
20. Inhibition of endogenous expression of connective tissue growth factor by its antisense oligonucleotide and antisense RNA suppresses proliferation and migration of vascular endothelial cells
21. 3, promotes endothelial cell survival, and induces angiogenesis in vivo
22. Significant correlation between connective tissue growth factor gene expression and skin sclerosis in tissue sections from patients with systemic sclerosis
23. Connective tissue growth factor: A novel regulator of mucosal repair and fibrosis in inflammatory bowel disease?
24. Connective tissue growth factor is a regulator for fibrosis in human chronic pancreatitis
25. Identification of glycosylated 38-kDa connective tissue growth factor (IGFBP-related protein 2) and proteolytic fragments in human biological fluids, and up-regulation of IGFBP-rP2 expression by TGF-β in Hs578T human breast cancer cells
26. Advanced glycation end-products driven angiogenesis in vitro: Induction of the growth and tube formation of human microvascular endothelial cells through
27. 2-Microglobulin modified advanced glycation end products modulates collagen synthesis in human fibroblasts
28. N(ε)-(Carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression
29. Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): Characterization of connective tissue growth factor as a member of the IGFBP superfamily
30. ras-dependent mitogen activated protein kinase pathway regulated by oxidant stress
31. Advanced glycation end products increase retinal vascular endothelial growth factor expression
32. Orally absorbed reactive glycation products (glycotoxins): An environmental risk factor in diabetic nephropathy
33. Insulin-like growth factor-I (IGF-I) and transforming growth factor-β1 release IGF-binding protein-3 from human fibroblasts by different mechanisms
34. Developmental regulation of Mac25/insulin-llke growth factor-binding protein-7 expression in skeletal myogenesis
35. Regulation of connective tissue growth factor gene expression in human skIn fibroblasts and during wound repair
36. Advanced glycation end product (AGE)-mediated induction of tissue factor in cultured endothelial cells is dependent on RAGE
37. Enhanced interaction of advanced glycation end products with their cellular receptor RAGE: Implications for the pathogenesis of accelerated periodontal disease in diabetes
38. Characterization of cell-associated and soluble forms of connective tissue growth factor (CTGF) produced by fibroblast cells in vitro
39. Determination of advanced glycation end products in serum by fluorescence spectroscopy and competitive ELISA
40. Immunochemical detection of advanced glycosylation end products in vivo
41. Structure of a synthetic glucose derived advanced glycation end product that is immunologically cross-reactive with its naturally occurring counterparts
42. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts
43. What's the RAGE? The receptor for advanced glycation end products (RAGE) and the dark side of glucose
44. Connective tissue growth factor mediates transforming growth factor beta-induced collagen synthesis: Down-regulation by cAMP
45. Suppression subtractive hybridization identifies high glucose levels as a stimulus for expression of connective tissue growth factor and other genes in human mesangial cells
46. Regulation of connective tissue growth factor activity in cultured rat mesangial cells and its expression in experimental diabetic glomerulosclerosis
47. Expression of connective tissue growth factor in human renal fibrosis
48. Human connective tissue growth factor is expressed in advanced atherosclerotic lesions
49. A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene
50. Dexamethasone is a novel potent inducer of connective tissue growth factor expression. Implications for glucocorticoid therapy
51. Cutaneous manifestations of diabetes mellitus
52. Pathologic features of diabetic thick skin
53. Digital sclerosis in children with insulin-dependent diabetes mellitus
54. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis
55. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits